JP2023510737A - 免疫調節剤 - Google Patents

免疫調節剤 Download PDF

Info

Publication number
JP2023510737A
JP2023510737A JP2022541693A JP2022541693A JP2023510737A JP 2023510737 A JP2023510737 A JP 2023510737A JP 2022541693 A JP2022541693 A JP 2022541693A JP 2022541693 A JP2022541693 A JP 2022541693A JP 2023510737 A JP2023510737 A JP 2023510737A
Authority
JP
Japan
Prior art keywords
acceptable salt
subject
pharmaceutically acceptable
compound
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022541693A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510737A5 (cg-RX-API-DMAC7.html
Inventor
ワン,タオ
マイケル スコラ,ポール
ジャン,ジョンシン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2023510737A publication Critical patent/JP2023510737A/ja
Publication of JP2023510737A5 publication Critical patent/JP2023510737A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2022541693A 2020-01-06 2020-11-19 免疫調節剤 Pending JP2023510737A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062957383P 2020-01-06 2020-01-06
US62/957,383 2020-01-06
PCT/US2020/061273 WO2021141684A1 (en) 2020-01-06 2020-11-19 Immunomodulators

Publications (2)

Publication Number Publication Date
JP2023510737A true JP2023510737A (ja) 2023-03-15
JP2023510737A5 JP2023510737A5 (cg-RX-API-DMAC7.html) 2023-10-17

Family

ID=73835799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022541693A Pending JP2023510737A (ja) 2020-01-06 2020-11-19 免疫調節剤

Country Status (7)

Country Link
US (1) US12403174B2 (cg-RX-API-DMAC7.html)
EP (1) EP4087857B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023510737A (cg-RX-API-DMAC7.html)
KR (1) KR20220122752A (cg-RX-API-DMAC7.html)
CN (1) CN114929728A (cg-RX-API-DMAC7.html)
ES (1) ES2967135T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021141684A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220161407A (ko) 2020-03-30 2022-12-06 브리스톨-마이어스 스큅 컴퍼니 면역조정제
EP4499667A1 (en) * 2022-03-28 2025-02-05 Bristol-Myers Squibb Company Macrocyclic immunomodulators
US20260022142A1 (en) * 2022-05-20 2026-01-22 Bristol-Myers Squibb Company Macrocyclic immunomodulators
EP4578866A4 (en) * 2022-08-23 2025-12-03 Fujifilm Corp METHOD FOR PREDICTING THE CELL MEMBRANE PERMEABILITY OF A CYCLIC PEPTIDE
WO2024059472A1 (en) * 2022-09-12 2024-03-21 Bristol-Myers Squibb Company Macrocyclic immunomodulators
US20260132169A1 (en) * 2022-10-20 2026-05-14 Chugai Seiyaku Kabushiki Kaisha Method for producing cyclic peptide crystals

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520766A (ja) * 2012-05-21 2015-07-23 アジレント・テクノロジーズ・インクAgilent Technologies, Inc. 組成物及びオリゴヌクレオチドをコンジュゲートする方法
JP2016519062A (ja) * 2013-03-15 2016-06-30 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Pd−1/pd−l1およびcd80(b7−1)/pd−l1タンパク質/タンパク質相互作用の大環状阻害剤
JP2017536330A (ja) * 2014-09-11 2017-12-07 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Pd−1/pd−l1およびcd80(b7−1)/pd−l1タンパク質/タンパク質相互作用の大環状阻害剤
JP2018504379A (ja) * 2014-12-18 2018-02-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 免疫修飾因子
JP2019513734A (ja) * 2016-04-05 2019-05-30 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Pd−1/pd−l1およびcd80/pd−l1のタンパク質/タンパク質の相互作用の大環状阻害剤

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US9090668B2 (en) 2007-03-26 2015-07-28 The University Of Tokyo Process for synthesizing cyclic peptide compound
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
JP5818237B2 (ja) 2010-09-09 2015-11-18 国立大学法人 東京大学 N−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法
JP6206943B2 (ja) 2010-12-03 2017-10-04 国立大学法人 東京大学 ペプチドライブラリーの製造方法、ペプチドライブラリー、及びスクリーニング方法
EP2717895A1 (en) 2011-06-08 2014-04-16 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
WO2013010573A1 (en) 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
CN104245726A (zh) 2012-03-29 2014-12-24 奥瑞基尼探索技术有限公司 来自人pd1的bc环的免疫调节环状化合物
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo pH依存的に標的分子に結合するペプチドのスクリーニング方法
MX355396B (es) 2012-06-06 2018-04-18 Polyphor Ag Peptido - mimeticos de la horquilla beta.
US20150174235A1 (en) 2012-06-06 2015-06-25 Bionor Immuno As Vaccine
KR20150131269A (ko) 2013-03-15 2015-11-24 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
MX2016002970A (es) 2013-09-06 2016-10-07 Aurigene Discovery Tech Ltd Compuestos peptidomimeticos ciclicos como inmunomoduladores.
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
JP6622814B2 (ja) 2014-11-25 2019-12-18 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company イメージングのための新規pd−l1結合ポリペプチド
WO2016086036A2 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Methods and compositions for 18f-radiolabeling of biologics
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
WO2017201111A1 (en) 2016-05-19 2017-11-23 Bristol-Myers Squibb Company Pet-imaging immunomodulators
KR102526034B1 (ko) 2016-11-07 2023-04-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
CN110997698B (zh) * 2017-06-23 2023-12-26 百时美施贵宝公司 充当pd-1拮抗剂的免疫调节剂
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators
KR20220010535A (ko) 2019-05-21 2022-01-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
EP4051692A1 (en) 2019-10-30 2022-09-07 Bristol-Myers Squibb Company Immunomodulators
WO2021102143A1 (en) 2019-11-19 2021-05-27 Bristol-Myers Squibb Company Macrocyclic peptides as pd-l1 inhibitors and immunomodulators for the treatment of cancer and infectious diseases
WO2021141682A1 (en) 2020-01-06 2021-07-15 Bristol-Myers Squibb Company Macrocyclic peptides as pd-l1 inhibitors and immunomodulators for the treatment of cancer and infectious diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520766A (ja) * 2012-05-21 2015-07-23 アジレント・テクノロジーズ・インクAgilent Technologies, Inc. 組成物及びオリゴヌクレオチドをコンジュゲートする方法
JP2016519062A (ja) * 2013-03-15 2016-06-30 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Pd−1/pd−l1およびcd80(b7−1)/pd−l1タンパク質/タンパク質相互作用の大環状阻害剤
JP2017536330A (ja) * 2014-09-11 2017-12-07 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Pd−1/pd−l1およびcd80(b7−1)/pd−l1タンパク質/タンパク質相互作用の大環状阻害剤
JP2018504379A (ja) * 2014-12-18 2018-02-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 免疫修飾因子
JP2019513734A (ja) * 2016-04-05 2019-05-30 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Pd−1/pd−l1およびcd80/pd−l1のタンパク質/タンパク質の相互作用の大環状阻害剤

Also Published As

Publication number Publication date
ES2967135T3 (es) 2024-04-26
EP4087857A1 (en) 2022-11-16
CN114929728A (zh) 2022-08-19
EP4087857B1 (en) 2023-11-01
US12403174B2 (en) 2025-09-02
KR20220122752A (ko) 2022-09-02
WO2021141684A1 (en) 2021-07-15
US20230065827A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
JP7550864B2 (ja) 癌および感染症を治療するためのpd-l1阻害剤および免疫調節剤としての大環状ペプチド
EP4087857B1 (en) Immunomodulators
JP2023517736A (ja) 免疫調節剤
JP2023500834A (ja) 免疫調整剤
JP2023524813A (ja) 免疫調節剤
EP4126902B1 (en) Immunomodulators
EP4225774B1 (en) Macrocyclic immunomodulators
EP4225775B1 (en) Dimeric milla immunomodulators
JP2023544730A (ja) 大環状ペプチドボロネート免疫調節剤
JP2024516369A (ja) 環状ペプチド免疫調節剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250430